Gilead(US:GILD) Xin Lang Cai Jing·2026-02-11 15:36Core Viewpoint - Gilead Sciences (GILD.US) shares rose over 5% to a record high of $155.54 following the release of its financial results, indicating strong performance and growth potential in the market [1] Financial Performance - For the full year 2025, Gilead reported total revenue of $29.443 billion, representing a year-over-year increase of 2.4% [1] - The net profit attributable to the company was $8.51 billion, showing a significant year-over-year increase of approximately 16.73 times [1] - Non-GAAP diluted earnings per share reached $8.15, reflecting a substantial year-over-year growth of 77% [1] Product Development and Market Position - Gilead's Chairman and CEO, Daniel O'Day, highlighted that the previous year was fruitful for the company, marked by the successful launch of Yeztugo, the world's first semi-annual HIV prevention therapy [1] - The continued growth of Biktarvy and Descovy has established a solid foundation for the company's future growth [1]